Sandostatin: Clinical Trials

8 trials of Sandostatin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 terminated, 1 active not recruiting, 1 unknown. 8 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 28Completed 4, Terminated 2, Active not recruiting 1, Unknown 1
Phase 11Active not recruiting 1

Follow Sandostatin: new trials by email Literature Review of Sandostatin trials Research Report on Sandostatin

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
Sacituzumab Govitecan, EKG, Brain MRI - Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma
Phase 2TerminatedNational Cancer Institute (NCI)22025-06-092026-01-21
Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber
Octreotide LAR - Hereditary Hemorrhagic Telangiectasia, Gastrointestinal Hemorrhage
Phase 2UnknownRadboud University Medical Center152016-10-012018-04-20
Octreotide for Management of Bronchorrhea in Mechanically Ventilated Patients
Octreotide - Octreotide, Sputum
Phase 2CompletedDanbury Hospital52016-09-012020-10-08
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
Bevacizumab, Everolimus, Octreotide Acetate - Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor
Phase 2CompletedNational Cancer Institute (NCI)1502010-10-152022-08-04
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
AMG 706, octreotide - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Phase 2CompletedEastern Cooperative Oncology Group462008-11-072023-07-05
Sandostatin for Patients With Androgen Independent Prostate Cancer
Sandostatin - Prostate Cancer
Phase 2TerminatedUniversity of California, San Francisco132007-07-012013-12-11
Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer
octreotide acetate - Liver Cancer
Phase 2CompletedUNC Lineberger Comprehensive Cancer Center312005-07-012012-02-14
Treatment of Orthostatic Intolerance
Acetazolamide, Atomoxetine, NO Drug - Tachycardia, Chronic Orthostatic Intolerance
Phase 1 / Phase 2Active not recruitingSatish R. Raj1501997-04-012026-10-16

Conditions studied

Vipoma (2)  ·  Adenoma, Islet Cell (1)  ·  Anemia (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Islet Cell (1)  ·  Gastrinoma (1)  ·  Gastrointestinal Hemorrhage (1)  ·  Glucagonoma (1)  ·  Insulinoma (1)  ·  Liver Neoplasms (1)  ·  Neoplasms (1)  ·  Neuroendocrine Tumors (1)  ·  Postural Orthostatic Tachycardia Syndrome (1)  ·  Prostatic Neoplasms (1)  ·  Recurrence (1)

Sponsors

National Cancer Institute (NCI) (2)  ·  Danbury Hospital (1)  ·  Eastern Cooperative Oncology Group (1)  ·  Radboud University Medical Center (1)  ·  Satish R. Raj (1)  ·  UNC Lineberger Comprehensive Cancer Center (1)  ·  University of California, San Francisco (1)

Countries

United States (7)  ·  Canada (1)  ·  Netherlands (1)

Top investigators

Abhijith Hegde, MD (1)  ·  Bert H. O'Neil, MD (1)  ·  Charles Ryan, MD (1)  ·  Joost Drenth, MD PhD (1)  ·  Kevin C Conlon, M.D. (1)  ·  Mary Mulcahy, MD (1)  ·  Matthew H Kulke (1)  ·  Satish R Raj, MD MSCI (1)

Results publications

PMID 15911704, PMID 19687359, PMID 20884247, PMID 24002370, PMID 24227635, PMID 24495468, PMID 24606242, PMID 24721800, PMID 29853660, PMID 32673517

NIH funding

U10CA023318 (1), U10CA031946 (1), U10CA180821 (1), UL1TR000445 (1)